Voyager Therapeutics announces $100M common stock offering

Voyager Therapeutics announced that it has commenced an underwritten public offering of $100M of shares of its common stock. The company intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents and marketable securities, the $20M the company received from Novartis in January 2024 as consideration for the purchase of shares of its common stock and the additional $80M upfront payment the company anticipates receiving from Novartis in connection with the company’s entry into a strategic collaboration and a stock purchase agreement with Novartis in December 2023, to advance the company’s anti-tau antibody program for the treatment of Alzheimer’s disease and its SOD1 silencing gene therapy program for the treatment of amyotrophic lateral sclerosis into clinical development, to advance its tau silencing gene therapy program for the treatment of AD and its anti-amyloid gene therapy program for the treatment of AD in preclinical development, to support its other preclinical development programs, and for working capital and other general corporate purposes. Citigroup and Guggenheim are acting as joint book-running managers for the offering. Oppenheimer is acting as book-running manager for the offering.